6-Oxo-trans,trans-2,4-hexadienoic acid | 88973-46-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 6-Oxo-trans,trans-2,4-hexadienoic acid
• 英文别名: Acide formyl-5 pentadiene-2,4 oique；2E,4E-6-oxo-2,4-hexadienoic acid；trans,trans-muconaldehyde；(2E,4E)-6-oxohexa-2,4-dienoic acid
• CAS: 88973-46-0
• 化学式: C₆H₆O₃
• 分子量: 126.112
• InChiKey: MGCBXZGOSMSZBJ-ZPUQHVIOSA-N

物化性质

• 熔点：
  207 °C
• 沸点：
  174.21°C (rough estimate)
• 密度：
  1.2048 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-Oxo-trans,trans-2,4-hexadienoic acid 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以59%的产率得到6-羟基己-2,4-二烯酸
  参考文献：
  名称：

  Le Baut; Sparfel; Clairc, European Journal of Medicinal Chemistry, 1983, vol. 18, # 5, p. 447 - 455

  摘要：

  DOI：
• 作为产物：
  描述：

  2-Aethoxy-6-aethoxycarbonyl-Δ³-dihydro-pyran 在 KU-2 resin 对甲苯磺酸 作用下， 以 水 、 丙酮 、 苯 为溶剂， 反应 11.0h， 生成 6-Oxo-trans,trans-2,4-hexadienoic acid
  参考文献：
  名称：

  Makin, S. M.; Dobretsova, E. K.; Shavrygina, O. A., Journal of Organic Chemistry USSR (English Translation), 1987, vol. 23, p. 445 - 448

  摘要：

  DOI：

文献信息

• Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof
  申请人：Ham Young Jin

  公开号：US20080009509A1

  公开（公告）日：2008-01-10

  The present invention relates to a novel quinazoline derivative and a pharmaceutically acceptable salt thereof for inhibiting the growth of cancer cells, a method for the preparation thereof and a pharmaceutical composition comprising same as an active ingredient.

  本发明涉及一种新型的喹唑啉衍生物及其药学上可接受的盐，用于抑制癌细胞的生长，其制备方法以及包含其作为活性成分的制药组合物。
• Unsaturated fatty acid derivatives and their production
  申请人：SUMITOMO PHARMACEUTICALS COMPANY, LIMITED

  公开号：EP0183177A1

  公开（公告）日：1986-06-04

  A compound of the formula: wherein Y is a free or esterified carboxyl group, or a group of the formula: (wherein Ra and Rb are each independently a hydrogen atom, a C1-C4 alkyl group, a C3-C7 cycloalkyl group, a benzyl group, a phenyl group, a phenyl group substituted with a halogen atom or a C1-C4 alkyl group, or, when taken together with the adjacent nitrogen atom, they represent a 5 to 7 membered saturated heterocyclic goup); R' is a C1-C12 alkyl group, a C2-C12 alkenyl group, a C2-C12 alkynyl group, a C3-C10 cycloalkyl group, a C4-C10 cycloalkenyl group, a hydroxy C1-C13 alkyl group, an C1-C12 alkyl group substituted with a group of the formula: (wherein Rc and Rd are each independently a hydrogen atom, or a C,-C4 alkyl group), a C3-C10 heterocyclic group, a phenyl group optionally substituted with one to three substituents selected from the group consisting of halogen atom, hydroxyl group, C1-C4 alkyl group, trifluoromethyl group, C1-C4 alkoxy group, and group of the formula: (wherein Rc and Rd are as defined above) or a group of the formula: [wherein A is a C1-C7 alkylene chain and B is a C3-C10 cycloalkyl group, a C4-C10 cycloalkenyl group, a C1-C12 alkoxy group, a C1-C12 alkylthio group, a C3-C10 cycloalkoxy group, a C4-C10 cycloalkenyloxy group, a C3-C10 heterocyclic group, or a phenyl or phenoxy group optionally substituted with one to three substituents selected from the group consisting of halogen atom, hydroxy group, C1-C4 alkyl group, group of the formula: (wherein Rc and Rd are as defined above), trifluoromethyl group, C1-C4 alkylthio group and C,-C4 alkoxy group]; n is 2, 3 or 4; R2 and R3 are hydrogen atoms or, when taken together, they mean a single linkage to form a trans double bond between the adjacent carbon atoms, and E is a cis or trans vinylene group; provided that when n is 3 and R' is a n-octyl group, a 2-octenyl group or a 2,5-octadienyl group, R2 and R3 are hydrogen atoms, and that when n is 2, E is a trans vinylene group or a non-toxic pharmaceutically acceptable salt thereof. Said compound have potent anti-leucotriene B4 action, and are useful in the treatment of inflammation and allergy.

  式中的化合物 其中 Y 是游离的或酯化的羧基，或者是式中的基团： (其中 Ra 和 Rb 各自独立地为氢原子、C1-C4 烷基、C3-C7 环烷基、苄基、苯基、被卤素原子或 C1-C4 烷基取代的苯基，或当与相邻的氮原子结合时，它们代表 5 至 7 个成员的饱和杂环基团）；R' 是 C1-C12 烷基、C2-C12 烯基、C2-C12 炔基、C3-C10 环烷基、C4-C10 环烯基、羟基 C1-C13 烷基、被式中基团取代的 C1-C12 烷基： (其中 Rc 和 Rd 各自独立地为氢原子或 C,-C4烷基）、C3-C10 杂环基团、任选被一至三个取代基取代的苯基，这些取代基可选自卤素原子、羟基、C1-C4 烷基、三氟甲基、C1-C4 烷氧基和式中的基团： (其中 Rc 和 Rd 如上定义）或式中的基团： [其中 A 为 C1-C7 亚烷基链，B 为 C3-C10 环烷基、C4-C10 环烯基、C1-C12 烷氧基、C1-C12 硫代烷基、C3-C10 环烷氧基、C4-C10 环烯氧基、C3-C10 杂环基，或任选被 1 至 3 个取代基取代的苯基或苯氧基，取代基可选自卤素原子、羟基、C1-C4 烷基、式中的基团： (其中 Rc 和 Rd 如上定义）、三氟甲基、C1-C4 烷硫基和 C,-C4 烷氧基]；n 为 2、3 或 4；R2 和 R3 为氢原子，或当它们结合在一起时，表示在相邻碳原子之间形成反式双键的单链，且 E 为顺式或反式亚乙烯基；当 n 为 3，R'为正辛基、2-辛烯基或 2,5-辛二烯基时，R2 和 R3 为氢原子；当 n 为 2 时，E 为反式乙烯基或其无毒性的药学上可接受的盐。上述化合物具有强效的抗白三烯 B4 作用，可用于治疗炎症和过敏。
• Conversion of biomass to useful intermediates
  申请人：Alliance for Sustainable Energy, LLC

  公开号：US11326190B2

  公开（公告）日：2022-05-10

  An aspect of the present disclosure is a microbial cell that includes a genetic modification resulting in the expression of a deficient form of an endogenous dioxygenase, and a gene encoding an exogenous dioxygenase and a promoter sequence, where the endogenous dioxygenase includes PcaH and PcaG, the exogenous dioxygenase includes LigA and LigB, the microbial cell is capable of growth utilizing at least one of a cellulose decomposition molecule or a lignin decomposition molecule, and the microbial cell is capable of producing 2-hydroxy-2H-pyran-4,6-dicarboxylic acid.

  本公开的一个方面是一种微生物细胞，它包括导致表达内源二氧 化酶缺陷形式的遗传修饰，以及编码外源二氧 化酶的基因和启动子序列，其中内源二氧 化酶包括 PcaH 和 PcaG、外源二氧化酶包括 LigA 和 LigB，微生物细胞能够利用纤维素分解分子或木质素分解分子中的至少一种进行生长，微生物细胞能够产生 2-羟基-2H-吡喃-4,6-二羧酸。
• METHOD AND KITS FOR PREPARING MULTICOMPONENT NUCLEIC ACID CONSTRUCTS
  申请人：——

  公开号：US20020028444A1

  公开（公告）日：2002-03-07

  The invention provides a highly efficient, rapid, and cost effective method of linking nucleic acid components in a predetermined order to produce a nucleic acid multicomponent construct. The invention further provides nucleic acid components, each nucleic acid component comprising a double stranded nucleic acid molecule having at least one single stranded 5′ or 3′ terminal sequence, the terminal sequence having sufficient complementarity to either a terminal sequence in a separate nucleic acid component or to a sequence in a linking nucleic acid molecule so as to allow for specific annealing of complementary sequences and linkage of the components in a predetermined order. Kits containing reagents required to practice the method of the invention are also provided.

  本发明提供了一种高效、快速、低成本的方法，可按预定顺序连接核酸组分，以产生核酸多组分构建体。本发明进一步提供了核酸组分，每个核酸组分包括双链核酸分子，该双链核酸分子具有至少一个单链 5′或 3′末端序列，该末端序列与单独核酸组分中的末端序列或与连接核酸分子中的序列具有足够的互补性，从而允许互补序列的特异性退火和组分按预定顺序连接。此外，还提供了含有实施本发明方法所需试剂的试剂盒。
• Methods and compositions for cellular and metabolic engineering
  申请人：Affymax Technologies N.V.

  公开号：US20030082611A1

  公开（公告）日：2003-05-01

  The present invention is generally directed to the evolution of new metabolic pathways and the enhancement of bioprocessing through a process herein termed recursive sequence recombination. Recursive sequence recombination entails performing iterative cycles of recombination and screening or selection to “evolve” individual genes, whole plasmids or viruses, multigene clusters, or even whole genomes. Such techniques do not require the extensive analysis and computation required by conventional methods for metabolic engineering.

  本发明一般针对新的代谢途径的进化，以及通过本文称为递归序列重组的过程提高生物处理能力。递归序列重组需要执行迭代循环重组和筛选或选择，以 "进化 "单个基因、整个质粒或病毒、多基因簇，甚至整个基因组。这种技术不需要传统代谢工程方法所需的大量分析和计算。